Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 18, 2022 08:06 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004

- Management to host the second webinar in ASLAN’s A4 series on Thursday, January 20, 2022, at 12:00pm ET MENLO PARK, Calif., and SINGAPORE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- ASLAN...
November 22, 2021 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

MENLO PARK, Calif. and SINGAPORE, Nov. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
April 22, 2021 07:51 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

SINGAPORE, April 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
March 03, 2021 00:42 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares

SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
March 01, 2021 16:01 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
February 25, 2021 06:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces $18 Million Private Placement

SINGAPORE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
January 26, 2021 07:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class

— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors — Data differentiates ASLAN003 from first...
January 11, 2021 05:34 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels - Data Monitoring...
November 19, 2020 07:22 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference

SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
November 09, 2020 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SINGAPORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...

Next Page keyboard_arrow_right